Mark Freijat, MD
Rheumatology · Scottsdale, AZNPI 1124337621
Payments from drug & device makers
Across 445 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Johnson & Johnson$932
- AbbVie$868
- GSK$864
- UCB, Inc.$635
- Pfizer$449
- plus $3K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 128 | $2,729 |
| Johnson & Johnson | 45 | $932 |
| AbbVie | 46 | $868 |
| GSK | 48 | $864 |
| UCB, Inc. | 27 | $635 |
| Pfizer | 26 | $449 |
| E.r. Squibb & Sons, L.L.C. | 19 | $437 |
| Actelion Pharmaceuticals US, Inc. | 6 | $410 |
| Sobi, Inc | 18 | $356 |
| Novartis | 11 | $312 |
| Mallinckrodt Hospital Products Inc. | 10 | $222 |
| Lilly USA, LLC | 11 | $213 |
| AstraZeneca | 7 | $182 |
| Akebia Therapeutics Inc | 1 | $140 |
| Sanofi | 7 | $139 |
| Aurinia Pharma U.S., Inc. | 5 | $110 |
| Sandoz | 5 | $97 |
| Bayer | 1 | $95 |
| Scilex Pharmaceuticals Inc. | 3 | $53 |
| Genentech USA, Inc. | 3 | $50 |
| Mylan Institutional Inc. | 2 | $50 |
| Biocon Biologics Inc | 2 | $43 |
| Qiagen, LLC | 2 | $43 |
| Boehringer Ingelheim | 2 | $39 |
| Celltrion USA Inc. | 2 | $38 |
| Ferring Pharmaceuticals Inc. | 2 | $30 |
| Almatica Pharma LLC | 1 | $24 |
| Grifols USA, LLC | 1 | $21 |
| Oxford Immunotec USA Inc | 1 | $20 |
| Nalu Medical, Inc. | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $17 |
| Avanos Medical | 1 | $12 |
How this compares
$9,647 in reported general payments places this provider in the 55th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Scottsdale
- Vivek NagarajaScottsdale$306K
- Winford GriffingScottsdale$145K
- Paul HowardScottsdale$124K
- Gary SilvermanScottsdale$109K
- Michael PhamScottsdale$66K
- Hani RashidScottsdale$26K
- Ramin SabahiScottsdale$13K
- Gabriel ColceriuScottsdale$13K
- Lester MertzScottsdale$4K
- Megan SullivanScottsdale$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.